Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The Multiple Myeloma Debates /
Multiple Myeloma Debate 2014: Recent advances in multiple myeloma

30th - 31st Jan 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.02.14
Views: 5281
Rating:

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos discuss the highlights from the Multiple Myeloma Debate in Copenhagen

The panel discusses the most recent data presented on:

Current and emerging treatment paradigms:

Choice between sequential or combination therapy for MM

The role of new therapies such as pomalidomide

Role of carfilzomib plus melphalan and prednisone as the upfront therapy of elderly patients with MM

New agents, such as MLN-9708, (an oral proteasome inhibitor), and daratumumab (an anti-CD38 monoclonal antibody)

Relapsed MM:

Defining the correct sequence of novel agents in the treatment of relapsed MM

Recognising and responding to resistance in relapsed MM

Primary refractory or multiply-relapsed MM: What are our options?

Transplantation:

The role of allotransplant in the era of novel therapies

How salvage autologous stem cell transplantation (ASCT) can achieve sustained disease control in recurrent MM

Optimal pre-transplant therapy

Best practice for post transplantation consolidation and maintenance therapy

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation